We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 313

Patent held invalid for not meeting promise of improved therapeutic profile

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and

Intellectual property weekly abstract bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 2 2013

The Federal Court of Appeal (FCA) recently upheld the decision of the Trial Judge, holding that one claim of the patent at issue was valid and

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada, USA
  • -
  • May 22 2013

The Supreme Court has dismissed Eli Lilly of Canada Inc.’s leave on the issue, as summarized by the Court, as to whether the creation by the Federal

Industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Health Canada has opened a Consultation regarding Plain Language Labelling. It is open until September 2, 2014. Health Canada has opened a

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 22 2013

A Member of the Trade-marks Opposition Board (Member) refused the registration of MACDIMSUM for a variety of food and drink items (the Trade-mark

Leave to amend Statement of Defence denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 18 2011

Shire brought a motion seeking leave to amend its Statement of Defence to add a new defence of infringement as well as a defence of failure to mitigate

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 15 2013

Obviousness and lack of patentable subject matter were cited by the Examiner as the basis for rejecting the patent application before the Patent

Intellectual property weekly abstract bulletin - week of 7th October 2013

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 7 2013

The Federal Court has dismissed an application to prohibit the Minister of Health from issuing a Notice of Compliance to the Respondent Cobalt in

The Federal Court finds two generic company's allegations to be unjustified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Two PM(NOC) decisions relating to the same patent were recently released by the Federal Court. In both cases, the applications were allowed